Journals / Nöropsikiyatri Arşivi / 2009 / Cilt: 46 - Sayı: 4

Uzun süreli metilfenidat verilmesi genç sıçanların striatumunda lipid peroksidasyonunu indükler

Chronic administration of methylphenidate induces lipid peroxidation in the striatum of young rats

Pages
163–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future studies should be conducted to examine whether antioxidant supplementation can prevent the brain tissue from methylphenidate induced oxidative stress.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Methylphenidate is the most commonly prescribed psychostimulant and is indicated in the treatment of attention-deficit hyperactivity disorder.
📊
Key Findings & Data:Methods: Methylphenidate at doses of 2 mg/kg (n=10) and 10 mg/kg (n=10) via gavage was administered to young Wistar rats (n=10) for 5 weeks, whereas the controls (n=10) were given saline solution.
💡
Conclusion & Impact:Future studies should be conducted to examine whether antioxidant supplementation can prevent the brain tissue from methylphenidate induced oxidative stress.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Süperoksit dismutaz · Oksidatif stres · Sıçan

Abstract

Objective: Methylphenidate is the most commonly prescribed psychostimulant and is indicated in the treatment of attention-deficit hyperactivity disorder. There have been concerns about potential adverse effects of long-term methylphenidate administration on the brain. The purpose of this study is to investigate antioxidant system and lipid peroxidation in order to evaluate the potential adverse effects of methylphenidate on the brain. Methods: Methylphenidate at doses of 2 mg/kg (n=10) and 10 mg/kg (n=10) via gavage was administered to young Wistar rats (n=10) for 5 weeks, whereas the controls (n=10) were given saline solution. Methylphenidate and saline solution were given orally and twice daily to match human medication. Superoxide dismutase, glutathione peroxidase, and malondialdehyde were measured in hippocampus, cerebellum, striatum, and frontal cortex of rat brains. Results: Methylphenidate at doses of 2 mg/kg and 10 mg/kg increased the levels of malondialdehyde in the striatum compared to the control group (p<0.01). At a dose of 10 mg/kg, methylphenidate decreased the superoxide dismutase activity in the frontal cortex compared to 2 mg/kg methylphenidate (p<0.05). However, there was no effect on glutathione peroxidase activity. Discussion: The present study suggests that at doses of both 2 mg/kg and 10 mg/kg, the long-term methylphenidate treatment causes lipid peroxidation in the striatum of rat brain. Future studies should be conducted to examine whether antioxidant supplementation can prevent the brain tissue from methylphenidate induced oxidative stress.

Özet

Amaç: Metilfenidat DEHB tedavisinde etkinliği gösterilmiş olan ve en sık reçete edilen psikostimulandır. Uzun süreli metilfenidat kullanımının beyin üzerine olası yan etkileri ile ilgili kaygılar bulunmaktadır. Bu çalışmanın amacı metilfenidatın beyin üzerine olası yan etkilerini değerlendirmek için antioksidan sistemin ve lipid peroksidasyonunun araştırılmasıdır. Yöntemler: Çalışma dört-haftalık 30 erkek Wistar sıçanı üzerinde yapıldı. Sıçanlar üç gruba ayrıldı, sırasıyla ilk iki gruba 2 mg/kg (n=10) ve 10 mg/kg (n=10) metilfenidat, kontrol grubuna ise (n=10) serum fizyolojik verildi. Uygulama beş hafta boyunca, ilacın insanlara uygulama şekline uyumlu olarak gavaj ile oral yoldan ve günde iki kez yapıldı. Çalışmanın sonunda sıçanların hipokampus, serebellum, striatum ve frontal kortekslerinde süperoksit dismutaz, glutatyon peroksidaz ve malondialdehid düzeyleri ölçüldü. Bulgular: Kontrol grubu ile karşılaştırıldığında 2 mg/kg ve 10 mg/kg dozlarında metilfenidat striatumdaki malondialdehid düzeylerini artırdı (p <0.01). 2 mg/kg metilfenidat verilen grupla karşılaştırıldığında 10 mg/kg metilfenidat verilen grupta sadece frontal kortekste süperoksit dismutaz aktivitesinde bir azalma gözlendi (p <0.05). Bununla birlikte, glutatyon peroksidaz aktivitesinde gruplar arasında bir farklılık bulunmadı. Tartışma: Bu çalışma 2 mg/kg ve 10 mg/kg dozlarda metilfenidatın uzun süreli kullanımında genç sıçan beyinlerinin striatumunda lipid peroksidasyonuna neden olduğunu ileri sürmektedir. Buradan yola çıkarak olası metilfenidat kaynaklı oksidatif stresin önlenmesi için antioksidanların tedaviye eklenmesinin uygunluğunun araştırılması gerekli görünmektedir.

🔖

Cite This Article

TÜRKBAY, T., TOPAL, T., CÖNGÖLOĞLU, M. A., UYSAL, B., ÇAYCI, T., KORKMAZ, A. (2009). Uzun süreli metilfenidat verilmesi genç sıçanların striatumunda lipid peroksidasyonunu indükler. Nöropsikiyatri Arşivi, Cilt: 46 - Sayı: 4, 163–168. https://ajindex.com/articles/292784

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, 2000: pp.85-93
  2. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatr 2000; 157:816-8
  3. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000; 75:711-21
  4. Rappley MD. Clinical practice. Attention deficit-hyperactivity disorder. N Engl J Med 2005; 352:165-73
  5. Pliszka SR, Crismon ML, Hughes CW et al. for the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:642-57
  6. Spencer T, Biederman J, Wilens T et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35:409-32
  7. Zito JM, Safer DJ, dosReis S et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283:1025-30
  8. Axt KJ, Molliver ME. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse 1991; 9:302-13
  9. Frey K, Kilbourn M, Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 1997; 334:273-9
  10. Villemagne V, Yuan J, Wong DF et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C] WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998; 18:419-27
  11. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 1999; 19:1484-91
  12. Page G, Peeters M, Najimi M et al. Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes. J Neurochem 2001; 76:1282-90
  13. Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occ